Alkermes' alixorexton药物在治疗2型精神病治疗方面取得了显著成果,达到了关键目标,并为从2026年开始的大型试验铺平了道路。 Alkermes' alixorexton drug showed strong results in treating narcolepsy type 2, meeting key goals and paving the way for larger trials starting in 2026.

Alkermes 宣布其口服食欲素 2 受体激动剂阿利索孕酮在 2 型发作性睡病患者中的 2 期 Vibrance-2 试验取得了积极的顶线结果。 Alkermes announced positive topline results from its Phase 2 Vibrance-2 trial of alixorexton, an oral orexin 2 receptor agonist, in patients with narcolepsy type 2. 该药物达到了其主要终点,在经过8周的治疗后,在觉醒和日间睡眠方面有显著改善,14毫克和18毫克剂量表现最佳。 The drug met its primary endpoints, showing significant improvements in wakefulness and daytime sleepiness after eight weeks of treatment, with the 14 mg and 18 mg doses performing best. 药物是完全容忍的,没有严重的安全问题。 The medication was well tolerated, with no serious safety concerns. 这些成果支持了将 alixorexton 推进到第3阶段对两种精神病的试验,第3阶段对NT2的试验预计将于2026年初开始。 These results support advancing alixorexton into Phase 3 trials for both narcolepsy types, with a Phase 3 trial in NT2 expected to begin in early 2026.